ADZYNMA

This brand name is authorized in Austria, Estonia, France, Ireland, Italy, Lithuania, Romania, UK.

Active ingredients

The drug ADZYNMA contains one active pharmaceutical ingredient (API):

1	rADAMTS13 UNII U5SFU33XUX - APADAMTASE ALFA
	rADAMTS13 is a recombinant form of the endogenous ADAMTS13. ADAMTS13 is a plasma zinc metalloprotease that regulates the activity of von Willebrand factor (VWF) by cleaving large and ultra-large VWF multimers to smaller units and thereby reducing the platelet binding properties of VWF and its propensity to form microthrombi. rADAMTS13 is expected to reduce or eliminate the spontaneous formation of VWF-platelet microthrombi that leads to platelet consumption and thrombocytopenia in patients with cTTP.
	Read more about Apadamtase alfa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ADZYNMA Powder and solvent for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AD13		B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AD Enzymes
Discover more medicines within B01AD13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3106011, 3106022
FR	Base de données publique des médicaments	62352670, 66193589
IT	Agenzia del Farmaco	051479018, 051479020
LT	Valstybinė vaistų kontrolės tarnyba	1100802, 1100803
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W70652001, W70653001